-
Proactive risk management – MIMS – Optimising the safe and effective use of medicines
Oct 1, 2024, 00:00 -
PRAC meeting highlights 30 September - 3 October 2024
Sep 30, 2024, 00:00 -
Oral Retinoids (acitretin and isotretinoin) - Reminder of the Pregnancy Prevention Programme
Sep 25, 2024, 16:33 -
Hydroxycarbamide-containing medicinal products – Potential interference with continuous glucose monitoring systems
Sep 20, 2024, 00:00 -
Eldepryl 5 mg tablets – PA1327/003/001 – One batch
Sep 16, 2024, 10:51 -
Terbasil 250mg tablets – PA2315/099/001 – One batch
Sep 13, 2024, 15:40 -
PRAC meeting highlights 2-5 September 2024
Sep 2, 2024, 00:00 -
Adverse reaction reporting - MIMS Reminder on the importance of reporting adverse drug reactions (Sept)
Sep 1, 2024, 00:00 -
NSAIDs – IMF – Updated recommendations for use during pregnancy
Sep 1, 2024, 00:00 -
McGrath MAC Video Laryngoscope – Priority 1 – For Immediate Action
Aug 27, 2024, 09:59 -
Glatiramer Acetate – Risk of anaphylactic reactions
Aug 14, 2024, 00:00 -
Spironolactone 100mg film-coated tablets – PA2315/119/003 – One batch
Aug 9, 2024, 15:50 -
Senvelgo 15 mg/ml oral solution for cats – Correct use of product in cats with diabetes
Jul 19, 2024, 14:43 -
CD19 or BCMA directed CAR T-cell therapies – Risk of secondary malignancy of T-cell origin
Jul 18, 2024, 08:52 -
17-Hydroxyprogesterone caproate – Suspension of marketing authorisation
Jul 17, 2024, 08:55 -
HeartSine Samaritan®PAD (Public Access Defibrillator) 350P/360P/450P/500P, Omron HDF-3500 - HPRA Safety Notice - Priority 2 – Warning
Jul 10, 2024, 00:00 -
Atomoxetine Accord 10/18/25/40/60/80/100 mg Hard Capsules – PA2315/019/001-007
Jul 9, 2024, 11:18 -
PRAC meeting highlights 8-11 July 2024
Jul 8, 2024, 00:00 -
Adverse reaction reporting - MIMS Reminder on the importance of reporting adverse drug reactions (July)
Jul 1, 2024, 00:00 -
Palmeux 75 mg and 150 mg prolonged-release suspension for injection – PA1142/040/003, 005 – One batch each
Jun 28, 2024, 12:55
